These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33963663)

  • 1. Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.
    de Brot S; Lothion-Roy J; Grau-Roma L; White E; Guscetti F; Rubin MA; Mongan NP
    Vet Comp Oncol; 2022 Mar; 20(1):38-49. PubMed ID: 33963663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective detection of BRAF
    Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
    Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
    Chastain EC; Oliva IV; Osunkoya AO
    Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating PSMA differential expression in canine uroepithelial carcinomas to aid disease-based stratification and guide therapeutic selection.
    Berry MR; Fadl-Alla BA; Samuelson J; Rosol TJ; Fan TM
    BMC Vet Res; 2022 Dec; 18(1):441. PubMed ID: 36539731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    Fonseca-Alves CE; Kobayashi PE; Rivera Calderón LG; Felisbino SL; Rinaldi JC; Drigo SA; Rogatto SR; Laufer-Amorim R
    PLoS One; 2018; 13(6):e0199173. PubMed ID: 29894516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of D2-40, Cytokeratin 5/6, and High-Molecular-weight Cytokeratin (Clone 34βE12) in Distinguishing Intraductal Spread of Urothelial Carcinoma From Prostatic Stromal Invasion.
    Iakymenko OA; Briski LM; Delma KS; Jorda M; Kryvenko ON
    Am J Surg Pathol; 2022 Apr; 46(4):454-463. PubMed ID: 34560681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors.
    Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC
    Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
    Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
    Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
    Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.
    Varma M; Morgan M; Amin MB; Wozniak S; Jasani B
    Histopathology; 2003 Feb; 42(2):167-72. PubMed ID: 12558749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry in diagnostic surgical pathology of the prostate.
    Hameed O; Humphrey PA
    Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
    Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
    Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in expression of uroplakin III, cytokeratin 7, and cyclooxygenase-2 in canine proliferative urothelial lesions of the urinary bladder.
    Sledge DG; Patrick DJ; Fitzgerald SD; Xie Y; Kiupel M
    Vet Pathol; 2015 Jan; 52(1):74-82. PubMed ID: 24608632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
    Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC
    Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
    Chan E; Garg K; Stohr BA
    Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Fibromyxoid Stromal Response is Associated with Muscle Invasion in Canine Urothelial Carcinoma.
    de Brot S; Grau-Roma L; Stirling-Stainsby C; Dettwiler M; Guscetti F; Meier D; Scase T; Robinson BD; Gardner D; Mongan NP
    J Comp Pathol; 2019 May; 169():35-46. PubMed ID: 31159949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
    Zhou M; Shah R; Shen R; Rubin MA
    Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.